Marisa Wexler, MS, senior science writer —

The long-acting complement inhibitor Ultomiris (ravulizumab-cwvz) has been approved by the U.S. Food and Drug Administration (FDA) to treat most adults with generalized myasthenia gravis (gMG). The approval specifically covers patients who are positive for antibodies against the acetylcholine receptor (AChR) — about 80% of gMG patients. “With the…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Treatment with Ultomiris (ravulizumab-cwvz) eased symptoms of generalized myasthenia gravis (gMG) for more than a year, according to new data from the ongoing CHAMPION-MG extension study. Findings were shared at the 2022 American Academy of Neurology (AAN) Annual Meeting in an oral presentation, titled “Long-term Efficacy…

Many people with myasthenia gravis (MG) caused by antibodies against MuSK initially present with eye-related symptoms, which soon affect other parts of the body, according to a new study. “The present study provides a better understanding of MuSK-MG disease and its clinical course,” its researchers wrote. The study, “…

Soliris (eculizumab) is better than rituximab at controlling myasthenia gravis (MG) symptoms over a two-year period, according to a new analysis. Results were detailed in the study, “Eculizumab versus rituximab in generalised myasthenia gravis,” published in the Journal of Neurology, Neurosurgery and Psychiatry. Soliris…

Cabaletta Bio has been cleared by the U.S. Food and Drug Administration (FDA) to start first-in-human clinical testing of MuSK-CAART, a cell-based therapy being developed to improve muscle strength in people with MuSK antibody-positive myasthenia gravis and help them in their activities of daily living. “We look forward to…

The risk of myasthenia gravis (MG) worsening during pregnancy is about 34%, a new study estimates. Notably, most MG pregnancies end in vaginal delivery, and the risk of preterm birth is not increased in women with the neuromuscular condition, the study also indicates. “The current study allows the current…

Scientists described a new cellular model of the neuromuscular junction that could be useful for diagnosing myasthenia gravis (MG) or developing new treatments for the condition. “New approaches for the treatment of neurodegenerative diseases are sorely needed, as decades of research have resulted in limited therapeutic advances. We hope…

By analyzing available research and conducting nearly 100 interviews with patients, an international team of researchers crafted a new tool to measure the severity of myasthenia gravis (MG) based on patient experiences. Called MG Symptoms PRO, this tool has the potential to aid clinical trials by better capturing a…

Argenx is working toward the commercial launch of Vyvgart (efgartigimod) — recently approved by the U.S. Food and Drug Administration (FDA) — to treat adults in the U.S. with generalized myasthenia gravis (gMG) who have the most common type of MG-driving antibody. Vyvgart currently is up for…